Group 1 - The Hong Kong stock market showed mixed performance on February 3, with the Hang Seng Index rising by 0.2%, while the Hang Seng Tech Index and the National Enterprises Index fell by 1.32% and 0.22% respectively [1] - The decline in tech stocks was attributed to investor concerns over potential increases in value-added tax (VAT) for internet service companies, following a VAT hike for Chinese telecom stocks [1] - Institutions believe that the concerns regarding tax increases for internet companies are exaggerated and lack solid evidence, noting that any tax hikes would contradict current policies aimed at promoting consumption [1] Group 2 - GF Securities indicated that the global dollar cycle is at a peak and is now in a decline phase, while the RMB has transitioned from depreciation to a mild appreciation, creating a favorable revaluation window for Chinese equity assets [2] - The report suggests embedding currency logic into asset allocation, focusing on "core manufacturing assets + beneficiaries of appreciation" in A-shares, and prioritizing sectors sensitive to import costs and high-quality liquid stocks in Hong Kong [2] - The Hong Kong Stock Connect Internet ETF (520910) tracks the CSI Hong Kong Stock Connect Internet Index, focusing on leading internet companies such as Alibaba, Tencent, Meituan, and Kuaishou, which are expected to benefit from AI penetration [2]

Group 1 - The pharmaceutical and biotechnology sector has shown strong capital attraction, with significant market sentiment recovery, as evidenced by the net inflow of 667 million yuan into the Kexin Innovation Drug ETF (589720) over ten consecutive trading days [1] - Recent mergers and acquisitions, such as China National Pharmaceutical's acquisition of Hejia Bio for 1.2 billion yuan and Rongchang Bio's exclusive licensing agreement with AbbVie worth up to 650 million USD, have boosted market confidence and highlighted the internationalization efforts of Chinese pharmaceutical companies [1] - The investment logic in the pharmaceutical sector is supported by "innovation realization" and "valuation repair," with domestic innovative drugs entering a commercialization and internationalization phase, indicating improved cash flow for leading pharmaceutical companies [1] Group 2 - The policy environment is increasingly supportive, with the Ministry of Commerce and other departments issuing guidelines to promote high-quality development in the pharmaceutical retail sector, encouraging mergers and acquisitions, which may lead to increased industry concentration [2] - Comprehensive support for innovative drug development through policy implementation lays a foundation for sustained growth in the industry [2] - The Kexin Innovation Drug ETF (589720) closely tracks the Kexin Innovation Drug Index, focusing on leading companies, with over 90% of its holdings in innovative drug firms, making it an attractive option for interested investors [2]

Market Overview - The A-share market experienced a significant decline, with the Shanghai Composite Index dropping 2.48% to 4015.75 points and the Shenzhen Component Index falling 2.69% to 13824.35 points, as trading volume reached 2.6 trillion yuan, slightly lower than the previous day [1] - The market sentiment was negatively impacted by the nomination of Kevin Warsh as the next Federal Reserve Chairman, raising concerns about prolonged high interest rates and a notable drop in risk appetite [1] Pharmaceutical and Biotech Sector - The pharmaceutical and biotech sector demonstrated strong capital attraction, with the Guotai Innovation Drug ETF (589720) seeing a net inflow of 667 million yuan over ten consecutive trading days [3][4] - Key mergers and acquisitions, such as China Biopharmaceutical's acquisition of Hejia Biotech for 1.2 billion yuan and Rongchang Biopharmaceutical's exclusive licensing agreement with AbbVie worth up to 650 million USD, have boosted market confidence and highlighted the global competitiveness of Chinese pharmaceutical companies [3][4] - The investment logic in the pharmaceutical sector is supported by "innovation realization" and "valuation recovery," as domestic innovative drugs enter a commercialization and internationalization phase [3][4] Solar Energy Sector - The solar energy sector saw a strong performance, with the solar industry index rising over 2% before retreating, driven by Tesla CEO Elon Musk's proposal for a "space solar" project [5][6] - The sector is transitioning from a "post-decline rebound" to a deeper "supply-demand pattern reshaping," with significant potential for Chinese solar companies due to their advantages in equipment and core material supply [5][6] - The solar industry has faced intense price competition, leading to significant losses for major players, but recent policies aimed at reducing competition and clearing out outdated capacity are expected to enhance market concentration and improve the profitability of leading firms [5][6] Electric Grid Sector - The electric grid sector is experiencing robust domestic demand, with transformer factories in regions like Guangdong and Jiangsu operating at full capacity, and significant investments expected from the State Grid Corporation [7][8] - Major electric grid equipment companies reported impressive earnings, with projected revenues of 21.205 billion yuan, a 37.18% increase year-on-year, and net profits of 3.163 billion yuan, up 54.35% from the previous year [7][8] - The global energy transition is driving demand for electric grid construction, particularly in underdeveloped regions, presenting substantial growth opportunities for domestic electric grid companies [7][8] Precious Metals Sector - The precious metals sector, particularly gold, is undergoing significant volatility, with COMEX gold prices dropping below 4500 [9][10] - Concerns over monetary policy tightening following Warsh's nomination have led to market sell-offs, exacerbated by high leverage and profit-taking after previous price surges [9][10] - Despite short-term adjustments, long-term support for gold prices remains due to expectations of Federal Reserve rate cuts and ongoing geopolitical tensions [9][10]

2026.02. 02 白酒板块逆市上涨 本文字数：2588，阅读时长大约4分钟 作者 | 第一财经 曹璐 历经四年深度调整的白酒板块，近期似乎出现了一线转机。 2月2日，A股市场整体走弱，上证指数下跌2.48%。白酒板块却在此时逆势上扬，相关ETF强势领涨，成为市场中的亮点。这已是该板块近期第二次在 调整市中率先反弹。但上一次大涨后迅速回调的"一日游"行情，仍让市场心有余悸。 更值得关注的是其背后的资金分歧。截至去年四季度末，公募白酒基金持仓已降至不足4%，筹码结构的出清看似为反转创造了条件，但机构与普通投 资者的操作却呈现显著分化。这波上涨究竟是长达四年调整后的"王者归来"，还是悲观预期修复下的短暂反弹？ "近期白酒板块的反弹更多是短期基本面因素和交易因素的双重影响。"恒生前海消费升级混合基金经理胡启聪从交易层面分析称，白酒板块整体的机构 持仓已降到历史低位，换言之筹码结构整体较好，抛压较少，"配合短期价格催化，极易引起资金的短期效益"。 不过，他也表示，大涨次日出现明显的调整，证明此次上涨更多是反弹，获利资金了结意愿强烈。"大家对于春节动销和茅台批价的分歧仍然较大，大 部分人并不相信白酒已经触底，而是抱 ...

Market Overview - The A-share market experienced a correction today, with the Shanghai Composite Index falling by 2.48% to close at 4015.75 points, and the Shenzhen Component Index dropping by 2.69% to 13824.35 points. Most sectors declined, with the precious metals sector nearly hitting the limit down, while only the food and beverage industry saw a slight increase. The market is currently in a deleveraging phase, indicating potential for further pullback, but as valuation pressures ease, new investment opportunities may gradually emerge [1] Solar Industry - The solar sector showed strong performance in the morning, with the solar industry index rising over 2% at one point, although it later retreated but still outperformed the broader market. Tesla CEO Elon Musk's recent proposal for "space solar" has opened new imaginative possibilities for the industry. Additionally, the Ministry of Industry and Information Technology held a meeting to address "involution" in the solar industry, emphasizing mergers and acquisitions and standard-setting to eliminate excessive competition. With the implementation of "anti-involution" policies and a surge in energy demand, the solar industry is expected to enter a recovery cycle characterized by simultaneous growth in volume and profit. For investors optimistic about energy transition and industry recovery, this may be an opportune time to consider the Guotai Solar ETF (159864) [1] Pharmaceutical and Biotech Sector - The pharmaceutical and biotech sector has demonstrated strong capital attraction recently, with market sentiment significantly improving. The investment rationale for the sector is primarily supported by "innovation realization" and "valuation recovery." Domestic innovative drugs are entering a phase of commercial explosion and internationalization. Furthermore, supportive policies from the Ministry of Commerce and other departments have been released to promote mergers and high-quality development in the pharmaceutical retail industry. The Biopharmaceutical ETF (512290) closely tracks the CSI Biopharmaceutical Index, encompassing both the growth potential of innovative drugs and the stability of medical device performance. This ETF's focus on leading companies and comprehensive industry coverage makes it a representative of core assets in China's biopharmaceutical industry, warranting investor attention [2] Electric Grid Sector - The Electric Grid ETF (561380) rose by 1.06% today. In terms of domestic demand, reports indicate that transformer factories in Guangdong and Jiangsu are operating at full capacity, with some orders for data center business extending to 2027. During the 14th Five-Year Plan, the State Grid Corporation's fixed asset investment is expected to reach 4 trillion yuan, a 40% increase compared to the previous plan. Additionally, the ongoing global energy transition is driving demand for new energy integration. The sector benefits from a combination of "order explosion, increased domestic investment, and overseas demand potential," supported by strong performance from leading grid equipment companies, making it a sector to watch for investors [2] Precious Metals Sector - The precious metals sector continued to experience significant adjustments today. Concerns over tightening U.S. monetary policy have heightened market sensitivity to negative news, leading to sharp corrections as a result of emotional and trading structure responses. However, long-term expectations regarding potential interest rate cuts by the Federal Reserve have not fundamentally changed, and geopolitical risks continue to provide long-term support for gold prices. In the short term, after the release of concentrated selling pressure, there may be a rebound and recovery window. In the medium to long term, the logic supporting gold prices remains intact, driven by the "Federal Reserve's rate cut cycle, increasing overseas uncertainties, and the global trend of de-dollarization." Investors are encouraged to monitor investment opportunities in the Guotai Gold ETF (518800) and Gold Stock ETF (517400) [3]

Core Viewpoint - The A-share market's liquor sector is experiencing a strong performance, with individual stocks showing a general upward trend as the traditional sales peak season approaches due to the upcoming Spring Festival [1] Group 1: Market Performance - The liquor sector index (BK0477) closed at 48,951.83, with a 1.23% increase, indicating a positive market sentiment [2] - Notable stocks such as Jinhuijiu and Huangtaijiu reached their daily limit, while others like Wuliangye and Moutai also saw significant gains [1][2] Group 2: Seasonal Factors - The upcoming Spring Festival is expected to boost sales in the liquor industry, with Moutai's price showing signs of recovery, providing strong price support for liquor stocks [1][3] - The 2026 Spring Festival is anticipated to have one additional day compared to previous years, which may enhance actual sales performance [1][3] Group 3: Macro Environment - The improvement in macroeconomic policies is seen as a positive factor for the liquor sector, with a focus on boosting domestic demand and real estate [3] - The government plans to implement a strategy for expanding domestic demand from 2026 to 2030, which could benefit the liquor industry [3] Group 4: Investment Sentiment - The allocation of public funds to the liquor sector has decreased to 3.93%, indicating a low historical level that may provide room for recovery [3] - Notable investor Duan Yongping expressed confidence in Moutai's stock price, suggesting it is undervalued from a long-term perspective [3] Group 5: Industry Outlook - Despite some companies facing earnings pressure, the valuation of the liquor sector is at historical lows, which may lead to a recovery ahead of earnings improvement [4] - Analysts believe that the liquor industry, as a barometer of the macro economy, is likely to benefit from government support for real estate and domestic demand [4]

Core Viewpoint - In January, the global asset allocation logic shifted from valuation recovery to profit-driven, with A-shares continuing an upward trend supported by policies, funding, and valuation [1][2]. Group 1: A-share Market Performance - The A-share market showed a steady upward trend in January, with the Shanghai Composite Index rising by 3.76%, the ChiNext Index by 4.47%, and the Shenzhen Index by 5.03% by the end of January [2]. - The non-ferrous metals sector led the gains with a 22.59% increase, followed by media, oil and petrochemicals, construction materials, and basic chemicals with respective increases of 17.94%, 16.31%, 13.31%, and 12.72% [2]. Group 2: Fund Performance - Public FOFs (funds of funds) performed well, with some products achieving monthly returns exceeding 30%. For instance, the Guotai Industry Rotation A fund had a monthly return of 30.31%, while the Guotai Preferred Navigation fund reached 37.12% [3][5]. - A total of 35 FOFs had monthly performance exceeding 10%, with 4 funds surpassing 20% [3]. Group 3: Market Trends and Predictions - Analysts noted that the core drivers of asset performance in January were cross-year capital reallocation and sentiment recovery, with expectations of a "spring excitement" in the stock market in the first quarter [3][7]. - The transition from valuation-driven to profit-driven narratives in global asset allocation is expected to continue, with a focus on sectors showing clear performance improvements, particularly in technology and cyclical industries [7]. Group 4: Fund Issuance and Research Activity - The issuance of public funds accelerated in January, with a significant number of FOFs focusing on themes like technological innovation and high-end manufacturing, reflecting market interest in economic transformation opportunities [6][7]. - A total of 156 public fund institutions participated in A-share research activities in January, covering 486 stocks across 30 first-level industries, indicating high research engagement [7].

跨年债市的关键：供需错配的节奏 20260201 摘要 超长债供需失衡是市场主导逻辑，配置需求不足时债市风险加大，需求 增加则利率修复。当前经济环境改善，利率震荡上行，但短期需警惕供 需错位，春节后操作需谨慎。 机构不缺资金但缺乏利率风险指标（VAE），大行负债稳定但贷款一般， 超长债发行对银行 EV 指标构成压力，监管限制下，银行需市场化手段 应对超长债发行压力。 地方债和特别国债发行通过套保机制将利率上行压力转移至长期国债， 未来需密切关注这些因素对市场的影响，操作上保持谨慎。 上半年债券市场供需矛盾难以彻底解决，不仅是央行投放资金问题，还 涉及利率风险指标的系统性影响。2 月地方债发行量预计达 9,000 亿至 1 万亿元，发行冲击或超预期。 10 年以内国债相对安全，30 年以上国债需关注地方债一级发行利率对 二级市场的影响。节后长久期资产供应增加，配置需求不足，需保持谨 慎。 Q&A 2025 年 12 月债市走弱，2026 年 1 月中下旬债市修复后，目前债市进入平 台期或瓶颈期。请问在这种情况下，年前和跨年后的机会点和风险点在哪里？ 当前债市的主要逻辑是供需关系。一季度甚至整个上半年，供需矛盾将 ...

行业周报 | 非银金融 券商业绩预告亮眼，保险有望延续估值修复 金融行业周报（2026/02/01） 金融行业周涨跌幅跟踪：1）本周非银金融（申万）指数涨跌幅为+1.04%， 跑赢沪深 300 指数 0.95pct。本周证券Ⅱ（申万）、保险Ⅱ（申万）、多元金 融指数涨跌幅分别为-0.69%、+5.50%、-3.62%。2）本周银行（申万）涨跌 幅为+0.86%，跑赢沪深 300 指数 0.78pct。其中，国有行、股份行、城商行、 农商行本周涨跌幅分别为+0.35%、-0.26%、+3.11%、+2.06%。 投资观点：1）保险：本周保险Ⅱ(申万)涨跌幅为+5.50%，跑赢沪深 300 指 数 5.42pct。1 月保险股受"开门红"业绩高涨，后因监管降温进入震荡回 调。展望 2 月，保险股有望延续估值修复趋势：负债端，居民挪储趋势持续， 分红险凭借"保底+浮动"的收益优势成为承接居民资产迁徙的核心品种， 叠加 1 月"开门红"高增态势延续，头部险企保费增速有望持续领跑；资产 端，股市慢牛预期升温叠加利率中枢企稳，板块有望逐步从"流动性宽松驱 动"向"宏观政策加码+经济修复预期驱动"切换，投资收益提升路径明确 ...

高能环境 20260129 摘要 高能环境通过收购湖南三家矿业公司获得金矿探矿权，标志着其业务从 再生资源向原生资源的重要拓展，预示着新的增长点。 2025 年业绩预告显示，高能环境归母净利润预计达 7.5 至 9 亿元，同 比增长显著，主要受益于金属价格上涨、新产能投产（如珠海新宏项 目）以及技改和产品升级。 受益于贵金属价格上涨，高能环境通过再生资源业务的价差收益和存货 增值，显著提升了运营利润，独特的商业模式使其充分受益于市场行情。 高能环境收购的四个金矿项目已探明储量约 4.5 吨黄金，品位为 3-6 克/ 吨，预计每吨净利可达 7 亿元以上，预计 2028 年开始产生实际收益。 未来，高能环境将侧重现有项目的精细化管理，扩展前端初始资源化和 加强中后端深度资源化，形成江西新科、金昌高能等核心企业联动的发 展模式。 公司正推进港股上市，积极拓展海外资源和环保业务，国际化是其长期 发展的重要战略方向，有望通过再融资布局国际市场。 金矿投产后，预计每年利润大致为 1.5 亿至 3 亿元，对应市值空间为 22.5 亿至 45 亿，加之未探明新矿的增长潜力，公司投资价值显著。 Q&A 高能环境在再生资源和矿产 ...